Published in Cancer Res on May 15, 2003
Human MicroRNA targets. PLoS Biol (2004) 34.51
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development. Mol Cell Biol (2006) 2.00
ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. Mol Cell (2009) 1.95
Methylation-acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol (2007) 1.75
The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A (2005) 1.73
The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol (2008) 1.33
A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A (2004) 1.33
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res (2007) 1.19
Comparative analyses by sequencing of transcriptomes during skeletal muscle development between pig breeds differing in muscle growth rate and fatness. PLoS One (2011) 1.19
Hbo1 Links p53-dependent stress signaling to DNA replication licensing. Mol Cell Biol (2007) 1.16
The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol (2009) 1.14
Structural insight into histone recognition by the ING PHD fingers. Curr Drug Targets (2009) 1.11
Reviewing the current classification of inhibitor of growth family proteins. Cancer Sci (2009) 1.09
Conserved molecular interactions within the HBO1 acetyltransferase complexes regulate cell proliferation. Mol Cell Biol (2011) 1.03
Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol (2009) 1.01
The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget (2015) 1.01
Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem (2011) 1.01
Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma. J Cancer Res Clin Oncol (2010) 1.01
p53 Acetylation: Regulation and Consequences. Cancers (Basel) (2014) 0.97
The MOZ histone acetyltransferase in epigenetic signaling and disease. J Cell Physiol (2014) 0.95
Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology (2010) 0.95
A targeted RNA interference screen reveals novel epigenetic factors that regulate herpesviral gene expression. MBio (2014) 0.95
MicroRNA-193 pro-proliferation effects for bone mesenchymal stem cells after low-level laser irradiation treatment through inhibitor of growth family, member 5. Stem Cells Dev (2012) 0.95
Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol (2011) 0.94
Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity. Proc Natl Acad Sci U S A (2010) 0.94
The inhibitor of growth protein 5 (ING5) depends on INCA1 as a co-factor for its antiproliferative effects. PLoS One (2011) 0.93
EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol (2010) 0.93
Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562. Clin Cancer Res (2009) 0.92
ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression. Oncotarget (2015) 0.91
ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer. Oncotarget (2015) 0.90
Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther (2010) 0.90
Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer. PLoS One (2012) 0.90
Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway. J Cancer Res Clin Oncol (2008) 0.89
A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res (2010) 0.87
Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density. J Cancer Res Clin Oncol (2012) 0.87
ING proteins as potential anticancer drug targets. Curr Drug Targets (2009) 0.87
The ING4 Binding with p53 and Induced p53 Acetylation were Attenuated by Human Papillomavirus 16 E6. PLoS One (2013) 0.86
Crystal structure of inhibitor of growth 4 (ING4) dimerization domain reveals functional organization of ING family of chromatin-binding proteins. J Biol Chem (2012) 0.85
Delivery of inhibitor of growth 4 (ING4) gene significantly inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells. Sci Rep (2014) 0.85
Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates. BMC Syst Biol (2008) 0.85
A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis. FEBS Lett (2008) 0.83
ING Genes Work as Tumor Suppressor Genes in the Carcinogenesis of Head and Neck Squamous Cell Carcinoma. J Oncol (2010) 0.83
Effect of the tumor suppressor gene ING4 on the proliferation of MCF-7 human breast cancer cells. Oncol Lett (2012) 0.83
Downregulation of inhibitor of growth 3 is correlated with tumorigenesis and progression of hepatocellular carcinoma. Oncol Lett (2012) 0.82
Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. Oncotarget (2015) 0.82
The Caenorhabditis elegans ing-3 gene regulates ionizing radiation-induced germ-cell apoptosis in a p53-associated pathway. Genetics (2008) 0.81
ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53. PLoS One (2015) 0.81
Synergistic tumor suppression by adenovirus-mediated ING4/PTEN double gene therapy for gastric cancer. Cancer Gene Ther (2015) 0.80
Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood (2012) 0.80
Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis. Cancer Res (2014) 0.80
The down-regulated ING5 expression in lung cancer: a potential target of gene therapy. Oncotarget (2016) 0.79
Recombinant ING4 suppresses the migration of SW579 thyroid cancer cells via epithelial to mesenchymal transition. Exp Ther Med (2015) 0.78
Low ING4 protein expression detected by paraffin-section immunohistochemistry is associated with poor prognosis in untreated patients with gastrointestinal stromal tumors. Gastric Cancer (2013) 0.78
Effects of long term low- and high-dose sodium arsenite exposure in human transitional cells. Am J Transl Res (2017) 0.77
SUMOylation of the ING1b tumor suppressor regulates gene transcription. Carcinogenesis (2014) 0.77
Patient outcome prediction using multiple biomarkers in human melanoma: A clinicopathological study of 118 cases. Exp Ther Med (2010) 0.77
Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma. Exp Mol Med (2017) 0.77
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol (2016) 0.77
Histones: Controlling Tumor Signaling Circuitry. J Carcinog Mutagen (2013) 0.77
SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer. Genes Dev (2015) 0.77
Mechanism of Histone H3K4me3 Recognition by the Plant Homeodomain of Inhibitor of Growth 3. J Biol Chem (2016) 0.76
MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. J Ovarian Res (2017) 0.75
Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo. Mol Med Rep (2016) 0.75
Cytoplasmic expression of p33(ING1b) is correlated with tumorigenesis and progression of human esophageal squamous cell carcinoma. Oncol Lett (2012) 0.75
Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer. J Ovarian Res (2016) 0.75
ING3 promotes prostate cancer growth by activating the androgen receptor. BMC Med (2017) 0.75
ING4 enhances paclitaxel's effect on colorectal cancer growth in vitro and in vivo. Int J Clin Exp Pathol (2015) 0.75
Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma. Oncol Lett (2016) 0.75
Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma. Oncol Lett (2017) 0.75
Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int J Mol Sci (2017) 0.75
INGs are potential drug targets for cancer. J Cancer Res Clin Oncol (2016) 0.75
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget (2017) 0.75
The roles of ING5 in gliomas: a good marker for tumorigenesis and a potential target for gene therapy. Oncotarget (2017) 0.75
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2004) 5.82
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell (2007) 3.68
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res (2008) 3.56
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J (2002) 3.29
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab (2005) 3.15
A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res (2013) 3.08
The landscape of recombination in African Americans. Nature (2011) 3.06
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res (2011) 2.81
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell (2006) 2.39
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol (2005) 2.31
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
TP53 and liver carcinogenesis. Hum Mutat (2003) 2.23
Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer (2006) 2.11
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle (2003) 2.10
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res (2004) 2.08
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res (2003) 1.97
The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell (2009) 1.96
A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. Immunity (2003) 1.95
Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One (2009) 1.94
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov (2013) 1.85
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell (2006) 1.82
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer (2010) 1.79
Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer (2007) 1.77
POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol (2005) 1.74
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J (2003) 1.71
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res (2005) 1.70
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet (2013) 1.69
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci U S A (2010) 1.66
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis (2004) 1.65
Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol (2002) 1.65
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol (2007) 1.64
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem (2003) 1.63
Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J Proteome Res (2006) 1.63